Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

Cision
Written By Health Wildcatters
Health Wildcatters
Previous

Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates
Next

AGILE CITY ANNOUNCES WINNERS OF INNOVATION GRANTS